A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure by Rutishauser, W.
European Heart Journal (1983) 4 (Supplement A). 149-152
A review of the long-term effects of prazosin and
hydralazine in chronic congestive heart failure
W . RUT1SHAUSER
Center of Cardiology. University Hospital.
Geneva. Switzerland
KEY WORDS: Congestive heart failure, prazosin, hydralazine.
In the last two years, six studies using prazosin in doses of 3—32 mg/day for two and 16 months have shown a
persistent but variable benefit in 50-8(f/o of those who initially responded favorably. However, serious side-effects
occurred in up to 40% and. in many cases, tolerance developed. Mortality was 25-38% in 3-6 months, 50% by one
year.
In five studies using hydralazine (sometimes combined with long acting nitrates). 150 patients observed from six
up to 29 months showed sustained benefit in 26 to 59%, while in many cases hemodynamic values returned to
pretreatment values. Again side-effects were considerable, with worsening of angina, fluid retention, gastro-
intestinal symptomatology and, rarelv. lupus ervthematodes. Mortality was 28—41% in 10-12 months, higher in
non-responders than in responders.
Although exercise capacity increased in responders. no data are available today to prove that these vasodilators
allow heart failure patients to live longer. Prudence is indicated in patients with congestive heart failure due to
coronary artery disease. Furthermore, tolerance development, which only may be surmountable if discontinuation
for a few weeks or switching to another drug is possible, is a serious problem limiting chronic vasodilator
application.
A
Heart failure is a state of abnormal cardiovascular
regulation in which the afterload mismatch is of
major importance'", fundamental compensatory
changes having led to an increase in peripheral
vascular resistance and an increase in heart size. Early
treatment by vasodilators would therefore delay, or
might even prevent heart failure: arterial dilatation
would lead to a better unloading of the ventricle
during systole, providing an increased muscle
shortening'"; venous dilatation together with
increased ventricular emptying would favor a
decrease in end-diastolic heart size'21. This attractive
hypothesis has been tested in congestive heart failure
and found to be true in several acute studies'3"5*.
For vasodilators to be effective in chronic heart
failure, the beneficial acute hemodynamic actions of
these agents should be maintained in long-term
treatment. An increase in exercise capacity or the
same exercise with more favorable hemodynamic
parameters is an important long-term goal. Optimally
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one would like naturally to see reduced morbidity
and mortality. Finally, these goals should be achieved
without major adverse side-effects.
This presentation reviews the results of treatment
with prazosin and hydralazine administered for
several months to patients in chronic heart failure.
Prazosin is mainly a postsynaptic alpha-adrenergic
blocker'61. It increases cardiac output and stroke
volume significantly during exercise and to a lesser
degree at rest, alpha-adrenergic blockade being more
evident during exercise'7'.
Recently, four studies have been reported using
prazosin in doses of 3-32 mg/day for 6-16 months
and involving 68 patients'8""*; in two further studies
treatment was only assessed for 2-3 months"2"13 ' .
All patients were in heart failure and treated
continuously with digitalis and diuretics. Table 1
gives details about the observed beneficial and side-
effects in these studies and their mortality.
Depending on the underlying degree of heart
failure and the level of sympathetic tone, the results
of the initial therapy may vary considerably. The
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Table I Recent long-term prazosin studies in patients with chronic congestive heart failure
Months n Dosage
(mg/day)
Beneficial effects Side-effecs Mortality at
2-3 6 12
months
Rouleau el a/.'"
A wan et al.m
Kucke/a/."01
Bertel el a/.""
Feldman et at}'1'
Coluccie/ a/."3)
Randomized double-
blind
159
12
6
6
3
2
34
16
10
8
13
10
3-21
8-32
15-20
3-20
5
16-24
If spironolactone added
good long-term effects
NYHA 4 - FT, persistent
symptomatic benefit
SVR during exercise and
PAP at rest and exercise
P < 005
CI and SV1 at rest
P < 005 exercise tolerance
improved
NYHA 3-7-2-3 , exercise
duration and EF P • 001
Spironolactone prevents
attenuation
Delayed tolerance in 30%
Hypotension in 40%
tendency to fluid retention
Orthostatic dizziness in 8%
In 30% deterioration
Increased diuretics
necessary
50%
Not mentioned
Not mentioned
25%
38%
Praz. 0%
Pbo. 17%
CI = cardiac index; EF = ejection fraction; NYHA = New York Heart Association classification; PAP = mean
pulmonary artery pressure; Pbo. = placebo; Praz. = prazosin; SVI = stroke volume index, SVR = systemic vascular
resistance.
4.>*ci
response to long-term therapy with prazosin depends
even more on the underlying cause and severity of
heart failure. Only' in a subset of patients did a
sustained beneficial effect persist, mainly during
exercise. The phenomenon of tolerance was observed
in most studies. The addition of spironolactone or an
increase of other diuretics may prevent attentuation.
Hydralazine has potent direct arteriolar dilatator
effect. In five recent studies using hydralazine (mostly
in doses up to 400 mg/day) a total of 150 patients
were observed for six to 29 months'14~18). About 20%
were considered early non-responders and about the
same percentage stopped therapy because of side-
effects. The main positive effects, as well as the
considerable adverse effects and the mortality of
these studies are summarized in Table 2. In these
Table 2 Recent long-term hydralazine and nitrate studies in patient with chronic congestive failure
Months n Dosage
(mg/day)
Beneficial effects Side-effects Mortality at
6 12 18
months
• C .
•
Morand el a/."*1 (H) 29
Massieeja/. I I 3 I(H + N) 13
Walsh er a/ ."6 ' (H + N) 10
Packer et a/."71 (H) 8-6
Matheyera/ ." 8 ' (H) 6
37 200-400
56
34
400
CI increased initially
80%*, later less difference
59% improvement by
NYHA-classes in 6
months
50% of patients main-
tained on therapy have
sustained benefit
11 Up to 900
12 100-300 6 months :CI + 59%*,
renal plasma flow + 35%*
Nausea, headaches, only
first month. 13%
antinuclear antibodies
Gastro-intestinal 32%,
headache 14%,
18% stopped therapy,
5% systemic lupus
erythematodes
21% early non-responders.
24% stop because side-
effects
32% 4 1 % > in
IHD
22% 37% 63%
0% R
87% NR
Not mentioned
Not mentioned k-
CI = cardiac index; IHD = ischemic heart disease; NR = non-responders, NYHA = New York Heart Association;
R = responders; H = hydralazine; N = nitrates.
*P < 005.
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studies, too, the pronounced initial hemodynamic
effect was attenuated in most patients with time and
benefit was sustained in only about half of those
patients maintained on therapy.
A tendency toward higher mortality is reported in
patients with heart failure due to coronary heart
disease*14'151. The effect on the coronary circulation
has to be considered. Reduced diastolic aortic
pressure means a generally reduced coronary
perfusion pressure. Therefore the flow through fixed
coronary stenoses decreases. A coronary steal
phenomenon can take place, leading to lactate
production"91.
Discussion
Even with vasodilators which have differing
molecular mechanisms and effects on regional flow,
the main problem in long-term use is an attenuation
of the desired effect in a high percentage of
patients'201. It is at the present not clear which subsets
of patients receive the greatest profit from a given
vasodilator. In severe heart failure with markedly
increased plasma levels of norepinephrine, but not
necessarily always increased renin-angiotensin, the
application of prazosin has been thought to be most
favorable. But a reduction of sympathetic activity
could be counteracted by the release of preformed
norepinephrine with no net effect on plasma'
norepinephrine levels*2 " . Furthermore the changes in
receptor sensitivity as documented, e.g. by the
blunted baroreceptor reflex in heart failure, may be
more important than the plasma level of a hormone.
Also since the sympathetic nervous system and the
renin-angiotensin system may be activated
independently in congestive heart failure, it is
understandable that inhibition of one system may not
give the desired response because of compensation by
the other1221. This reason may explain the fact that the
reaction to both prazosin and hydralazine in chronic
congestive failure varies, and that the chronic effects
are less evident than the acute.
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